To read the full story, subscribe or sign in.

Gates Foundation, Wellcome Trust set up drug development accelerator targeting COVID-19

March 10, 2020

LONDON – The Gates Foundation and Wellcome Trust have joined forces with financial services specialist Mastercard in establishing a $125 million seed fund to accelerate development of drugs to treat COVID -19.

BioWorld Asia Deals and M&A

Free access to BioWorld coronavirus articles

BioWorld

The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

Today's news in brief

BioWorld

BioWorld briefs for May 26, 2022.

Merck acquires global rights to cancer drug from Kelun in $1.4B deal

BioWorld

In a deal potentially worth more than $1.4 billion, Sichuan Kelun Pharmaceutical Co. Ltd. has out-licensed a large molecule drug in cancer to Merck & Co. Inc. for...

Today's news in brief

BioWorld MedTech

BioWorld MedTech's briefs for May 26.

Acea Pharma fails to win green light for abivertinib in China

BioWorld

Zhejiang Acea Pharmaceutical Co. Ltd. failed to obtain marketing approval from China’s NMPA for its third-generation EGFR tyrosine kinase inhibitor, abivertinib....

Upgrade your daily dose of biopharma and medtech news

Gates Foundation, Wellcome Trust set up drug development accelerator targeting COVID-19